Compare Moderna, Inc. (MRNA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VF Corp — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while VF Corp trades at $16.88 (market cap $6.62B). The key difference: Moderna, Inc. is far larger — about 3.6× VF Corp's market cap, and VF Corp pays a 2.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VFC | |
|---|---|---|
Market Cap | $23.60B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $21.55 |
52-Week Low | $22.36 | $11.66 |
Enterprise Value | $19.70B | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
VFC trades at $16.91, down 0.41% with a bearish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though recent quarters beat EPS estimates. Net income turned negative in 2025 at -$190M, but 2026 projections show recovery to $255M profit. Valuation metrics appear reasonable with P/E of 26.38 and P/S of 0.7, while analyst consensus targets $19.33 with 43% buy ratings.
VFC faces turnaround challenges with weak Vans performance and consumer headwinds, but improving margins and debt reduction provide catalysts. The stock offers potential upside to analyst targets if brand recovery continues, though execution risks remain elevated given recent volatility and competitive pressures in apparel retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
